ANN ARBOR, MI, USA I April 28, 2014 I NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine. HSV-2 is a leading cause of genital herpes, a sexually transmitted disease affecting over 45 million people in the U.S. Currently, there are no approved vaccines for HSV-2.
“When applied intranasally, our NE-adjuvanted vaccines provide enhanced protection against infection by eliciting both mucosal and systemic immunity,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research, NanoBio. “Mucosal immunity is particularly important for protecting against pathogens that enter the body across mucosal surfaces, including those associated with respiratory infections and sexually transmitted diseases.”
Dr. Fattom added, “At the ACVR, we will present data from pre-clinical guinea pig studies demonstrating the ability of NanoBio’s intranasal NE vaccine to enhance protection against HSV-2 as compared to leading intramuscular vaccine candidates. The data further indicates that this enhanced protection is a result of mucosal immunity that is elicited by intranasal NE vaccines. Based on these results, we are currently conducting additional studies in guinea pigs to optimize dosing. We expect to advance a NE vaccine candidate for HSV-2 into clinical testing in the near future.”
NanoBio’s NanoStat® technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. When applied intranasally, NE vaccines elicit mucosal immunity as well as systemic immunity.
Following are details of NanoBio’s upcoming oral presentation at the NFID’s Annual Conference on Vaccine Research:
Title: Nanoemulsion-Adjuvanted gD2 (NE80-gD2) Intranasal Vaccine Induces Robust Protection Against HSV-2 Challenge in a Guinea Pig Model
Presenter: Tarek Hamouda, MD, PhD, Sr. Director of Vaccine Research, NanoBio
Date/Time: April 28, 2014, from 3:30–3:45 p.m.
Location: The Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
About NanoBio
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit www.nanobio.com.
SOURCE: NanoBio
Post Views: 85
ANN ARBOR, MI, USA I April 28, 2014 I NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine. HSV-2 is a leading cause of genital herpes, a sexually transmitted disease affecting over 45 million people in the U.S. Currently, there are no approved vaccines for HSV-2.
“When applied intranasally, our NE-adjuvanted vaccines provide enhanced protection against infection by eliciting both mucosal and systemic immunity,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research, NanoBio. “Mucosal immunity is particularly important for protecting against pathogens that enter the body across mucosal surfaces, including those associated with respiratory infections and sexually transmitted diseases.”
Dr. Fattom added, “At the ACVR, we will present data from pre-clinical guinea pig studies demonstrating the ability of NanoBio’s intranasal NE vaccine to enhance protection against HSV-2 as compared to leading intramuscular vaccine candidates. The data further indicates that this enhanced protection is a result of mucosal immunity that is elicited by intranasal NE vaccines. Based on these results, we are currently conducting additional studies in guinea pigs to optimize dosing. We expect to advance a NE vaccine candidate for HSV-2 into clinical testing in the near future.”
NanoBio’s NanoStat® technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. When applied intranasally, NE vaccines elicit mucosal immunity as well as systemic immunity.
Following are details of NanoBio’s upcoming oral presentation at the NFID’s Annual Conference on Vaccine Research:
Title: Nanoemulsion-Adjuvanted gD2 (NE80-gD2) Intranasal Vaccine Induces Robust Protection Against HSV-2 Challenge in a Guinea Pig Model
Presenter: Tarek Hamouda, MD, PhD, Sr. Director of Vaccine Research, NanoBio
Date/Time: April 28, 2014, from 3:30–3:45 p.m.
Location: The Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
About NanoBio
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit www.nanobio.com.
SOURCE: NanoBio
Post Views: 85
